FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4223984604> ?p ?o ?g. }

• W4223984604 abstract "Normofractionated radiation regimes for definitive prostate cancer treatment usually extend over 7-8 weeks. Recently, moderate hypofractionation with doses per fraction between 2.2 and 4 Gy has been shown to be safe and feasible with oncologic non-inferiority compared to normofractionation. Radiobiologic considerations lead to the assumption that prostate cancer might benefit in particular from hypofractionation in terms of tumor control and toxicity. First data related to ultrahypofractionation demonstrate that the overall treatment time can be reduced to 5-7 fractions with single doses > 6 Gy safely, even with simultaneous focal boosting of macroscopic tumor(s). With MR-guided linear accelerators (MR-linacs) entering clinical routine, invasive fiducial implantations become unnecessary. The aim of the multicentric SMILE study is to evaluate the use of MRI-guided stereotactic radiotherapy for localized prostate cancer in 5 fractions regarding safety and feasibility.The study is designed as a prospective, one-armed, two-stage, multi-center phase-II-trial with 68 patients planned. Low- and intermediate-risk localized prostate cancer patients will be eligible for the study as well as early high-risk patients (cT3a and/or Gleason Score ≤ 8 and/or PSA ≤ 20 ng/ml) according to d'Amico. All patients will receive definitive MRI-guided stereotactic radiation therapy with a total dose of 37.5 Gy in 5 fractions (single dose 7.5 Gy) on alternating days. A focal simultaneous integrated boost to MRI-defined tumor(s) up to 40 Gy can optionally be applied. The primary composite endpoint includes the assessment of urogenital or gastrointestinal toxicity ≥ grade 2 or treatment-related discontinuation of therapy. The use of MRI-guided radiotherapy enables online plan adaptation and intrafractional gating to ensure optimal target volume coverage and protection of organs at risk.With moderate hypofractionation being the standard in definitive radiation therapy for localized prostate cancer at many institutions, ultrahypofractionation could be the next step towards reducing treatment time without compromising oncologic outcomes and toxicities. MRI-guided radiotherapy could qualify as an advantageous tool as no invasive procedures have to precede in therapeutic workflows. Furthermore, MRI guidance combined with gating and plan adaptation might be essential in order to increase treatment effectivity and reduce toxicity at the same time." @default.
• W4223984604 created "2022-04-19" @default.
• W4223984604 creator A5016681098 @default.
• W4223984604 creator A5023510680 @default.
• W4223984604 creator A5025604301 @default.
• W4223984604 creator A5027683337 @default.
• W4223984604 creator A5038323479 @default.
• W4223984604 creator A5054682137 @default.
• W4223984604 creator A5055289994 @default.
• W4223984604 creator A5063936976 @default.
• W4223984604 creator A5065547065 @default.
• W4223984604 creator A5070503392 @default.
• W4223984604 creator A5071865752 @default.
• W4223984604 creator A5072039956 @default.
• W4223984604 creator A5072272793 @default.
• W4223984604 creator A5078003238 @default.
• W4223984604 creator A5084052983 @default.
• W4223984604 date "2022-04-15" @default.
• W4223984604 modified "2023-10-15" @default.
• W4223984604 title "Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trial" @default.
• W4223984604 cites W1516952155 @default.
• W4223984604 cites W1827911007 @default.
• W4223984604 cites W1970186462 @default.
• W4223984604 cites W1983228790 @default.
• W4223984604 cites W1987470170 @default.
• W4223984604 cites W1989895459 @default.
• W4223984604 cites W1990510898 @default.
• W4223984604 cites W1991048589 @default.
• W4223984604 cites W1998994416 @default.
• W4223984604 cites W2002612178 @default.
• W4223984604 cites W2029409133 @default.
• W4223984604 cites W2040357326 @default.
• W4223984604 cites W2078270553 @default.
• W4223984604 cites W2094442174 @default.
• W4223984604 cites W2104631398 @default.
• W4223984604 cites W2111180711 @default.
• W4223984604 cites W2157634805 @default.
• W4223984604 cites W2164748078 @default.
• W4223984604 cites W2165244734 @default.
• W4223984604 cites W2165830113 @default.
• W4223984604 cites W2337386322 @default.
• W4223984604 cites W2465092116 @default.
• W4223984604 cites W2469323349 @default.
• W4223984604 cites W2744155804 @default.
• W4223984604 cites W2763991661 @default.
• W4223984604 cites W2769688243 @default.
• W4223984604 cites W2793551977 @default.
• W4223984604 cites W2886174490 @default.
• W4223984604 cites W2928985222 @default.
• W4223984604 cites W2932433038 @default.
• W4223984604 cites W2937088162 @default.
• W4223984604 cites W2952903287 @default.
• W4223984604 cites W2969176485 @default.
• W4223984604 cites W2973514824 @default.
• W4223984604 cites W3014131856 @default.
• W4223984604 cites W3035613691 @default.
• W4223984604 cites W3119005666 @default.
• W4223984604 cites W3125222626 @default.
• W4223984604 cites W3128646645 @default.
• W4223984604 doi "https://doi.org/10.1186/s13014-022-02047-w" @default.
• W4223984604 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35428327" @default.
• W4223984604 hasPublicationYear "2022" @default.
• W4223984604 type Work @default.
• W4223984604 citedByCount "4" @default.
• W4223984604 countsByYear W42239846042023 @default.
• W4223984604 crossrefType "journal-article" @default.
• W4223984604 hasAuthorship W4223984604A5016681098 @default.
• W4223984604 hasAuthorship W4223984604A5023510680 @default.
• W4223984604 hasAuthorship W4223984604A5025604301 @default.
• W4223984604 hasAuthorship W4223984604A5027683337 @default.
• W4223984604 hasAuthorship W4223984604A5038323479 @default.
• W4223984604 hasAuthorship W4223984604A5054682137 @default.
• W4223984604 hasAuthorship W4223984604A5055289994 @default.
• W4223984604 hasAuthorship W4223984604A5063936976 @default.
• W4223984604 hasAuthorship W4223984604A5065547065 @default.
• W4223984604 hasAuthorship W4223984604A5070503392 @default.
• W4223984604 hasAuthorship W4223984604A5071865752 @default.
• W4223984604 hasAuthorship W4223984604A5072039956 @default.
• W4223984604 hasAuthorship W4223984604A5072272793 @default.
• W4223984604 hasAuthorship W4223984604A5078003238 @default.
• W4223984604 hasAuthorship W4223984604A5084052983 @default.
• W4223984604 hasBestOaLocation W42239846041 @default.
• W4223984604 hasConcept C121608353 @default.
• W4223984604 hasConcept C126322002 @default.
• W4223984604 hasConcept C126838900 @default.
• W4223984604 hasConcept C133507102 @default.
• W4223984604 hasConcept C141071460 @default.
• W4223984604 hasConcept C155806632 @default.
• W4223984604 hasConcept C173974348 @default.
• W4223984604 hasConcept C188816634 @default.
• W4223984604 hasConcept C203092338 @default.
• W4223984604 hasConcept C2776235491 @default.
• W4223984604 hasConcept C2776651944 @default.
• W4223984604 hasConcept C2780192828 @default.
• W4223984604 hasConcept C2780387249 @default.
• W4223984604 hasConcept C2989005 @default.
• W4223984604 hasConcept C509974204 @default.
• W4223984604 hasConcept C535046627 @default.
• W4223984604 hasConcept C71924100 @default.
• W4223984604 hasConceptScore W4223984604C121608353 @default.

• next